BACKGROUND
The Chinese traditional medicine qiliqiangxin (QLQX) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) when added to guideline-directed medical therapy.
OBJECTIVES
This post hoc analysis of the QUEST (Qiliqiangxin in Heart Failure: Assessment of Reduction in Mortality)...
L. Shen, Jun-Ru Li, I. Cheang et al.· JACC. Heart failure· 0 citations
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of cardiovascular morbidity and mortality globally, despite recent advances in therapy, and new treatments that have added benefit are still needed. Qiliqiangxin (QLQX), a Traditional Chinese Medicine (TCM) formulation, has demonstrated...
I. Cheang, X. Zhu, L. Shen et al.· European Heart Journal· 0 citations
BACKGROUND
Low-density lipoprotein cholesterol (LDL-C) goal attainment is central to primary atherosclerotic cardiovascular disease (ASCVD) prevention, but LDL-C may not fully reflect the burden of apolipoprotein B (ApoB)-containing atherogenic particles. The prevalence and clinical correlates of residual ApoB elevatio...
Yan-Ping Shi, Yuan Tang, Meng-Ting Wang et al.· Diabetes, obesity and metabo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.